Jaguar Health, Inc. (JAGX) Form S-3 — Oct 22, 2026
Jaguar Health filed a new $75 million universal shelf registration statement on Form S-3, registering common stock, preferred stock, warrants, subscription rights and units for sale from time to time. The filing carries forward $41.56 million of unsold securities from its May 2024 shelf and registers $33.44 million of new capacity; no securities are being sold yet. The filing is a financing-enabling event rather than an actual offering, so the immediate impact is potential dilution overhang for JAGX, which last traded at $2.28 on October 21, 2026. The company has only about 2.32 million voting common shares outstanding, so any future takedown could be highly dilutive.
Key figures
- Gross Proceeds
- 75000000
- Offering Price
- 2.28
- Net fee due
- $2,909.36
- Newly registered amount
- $33,440,881.99
- Prior shelf sold amount
- $33,440,881.99
- Voting common shares outstanding
- 2323373
- Unsold securities carried forward
- $41,559,118.01 (Rule 415(a)(6)) from prior S-3 File No. 333-278861
- Last reported sale price 2026 10 21
- $2.28
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.